Life sciences companies across Europe are implementing forward-thinking strategies to not only meet the transparency requirements set forth by the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure Code now in effect but also to capture competitive advantage. Read how these process changes and new technologies support full transparency of HCP interactions and how they can drive your commercial operation forward in the US.
